



INVITATION

International Multidisciplinary
Symposium

**20–21 November
2026**

Klinik Floridsdorf
Brünner Straße 68
1210 Vienna
Austria



VITOS

Vienna International Thoracic Oncology Summit 2026

Local Chairs: T. Klikovits • S. Watzka

Program Committee: M. Hochmair, T. Klikovits, I. Opitz, A. Rimner, S. Watzka

Welcome Note

Dear Colleagues,

it is our distinct pleasure to invite you to the **Vienna International Thoracic Oncology Summit (VITOS)**, taking place in Vienna 20–21 November 2026.

This exclusive two-day scientific meeting will bring together an exceptional faculty of internationally renowned experts to discuss the latest developments in thoracic malignancies, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), mesothelioma and thymic malignancies. Through state-of-the-art lectures, expert panel discussions and interdisciplinary exchange, the Summit will highlight emerging scientific insights, innovative therapeutic strategies and future directions in thoracic oncology.



© private

Thomas Klikovits,
Klinik Floridsdorf, Vienna, Austria



© feelimage/Matern

Stefan Watzka,
Klinik Floridsdorf, Vienna, Austria

Hosted in the historic and inspiring city of Vienna, a long-standing center of medical excellence and scientific innovation, **VITOS** aims to create a distinguished platform for collaboration among leading clinicians and researchers from across the globe.

We are honored to welcome you to this unique gathering and look forward to two days of outstanding science, stimulating discussion and meaningful international exchange. We look forward to welcoming you to Vienna.



SESSION 1 (9 am – 10:30 am) – CET: Screening & Early stage NSCLC

- 20 min.** “Do we really need lung cancer screening – and who benefits most in 2026”
Helmut Prosch, Medical University of Vienna, Vienna, Austria
- 20 min.** “Blood based early detection – where are we?”
Rafael Rosell, Pangaia Oncology, Barcelona, Spain
- 20 min.** “Stage I NSCLC: Surgery in the era of sublobar resection and robotics”
Stephen Cassivi, Mayo Clinic, Rochester, Minnesota, USA
- 20 min.** “Is stereotactic radiation treatment less invasive while more effective than surgery?”
Andreas Rimner, University of Freiburg, Freiburg, Germany
- 10 min.** Discussion

BREAK (10:30 am – 11:00 am) – CET

SESSION 2 (11 am – 12:30 pm) – CET: Locally Advanced NSCLC – Resectability Redefined

- 25 min.** “Immunotherapy or targeted treatment: how does it affect pathological diagnosis?”
Luka Brcic, Medical University of Vienna, Vienna, Austria
- 25 min.** “Perioperative Treatment and borderline resectable NSCLC: the surgeons perspective”
Luca Bertolaccini, University of Milan & European Institute of Oncology IRCCS, Milan, Italy
- 25 min.** “(Neo)adjuvant or perioperative systemic treatment: the oncologists perspective”
Patrick Forde, Trinity College Dublin, Dublin, Ireland
- 15 min.** Discussion

LUNCH BREAK (12:30 pm – 1:30 pm) – CET

SESSION 3 (1:30 pm – 3 pm) – CET: Hot topics stage IV in 2026 – Precision, Resistance, and Beyond (including best of ASCO/ESMO/WCLC)

25 min. “Immunotherapy – beyond PD-1: combinations, biomarkers, sequencing”
Arnaud Scherpereel, Hospital of the University (CHU) of Lille, Lille, France

25 min. “Targeted treatment and ADCs”
Maximilian Hochmair, Klinik Floridsdorf, Vienna, Austria

25 min. “Oligometastatic NSCLC – who benefits from aggressive local therapy?”
Isabelle Opitz, University Hospital Zurich, Zurich, Switzerland

15 min. Discussion

BREAK (3 pm – 3:30 pm) – CET

SESSION 4 (3:30 pm – 5 pm) – CET: Interdisciplinary case discussion – Real World Decision Making

Case presentation

Marko Jakopovic, University of Zagreb, Zagreb, Croatia

Panel onsite experts

Luca Bertolaccini

Luka Brcic

Marko Jakopovic

Andreas Rimner

Arnaud Scherpereel

Helmut Prosch

REGISTRATION OPENS AT 8:30 am

SESSION 5 (9 am – 10:30 am) – CET: **State of the Art treatment for pleural mesothelioma –** **Is Multimodality Still Relevant?**

- 25 min.** “Is surgery +/- intracavitary treatment still appropriate?”
Servet Bölükbas, Ruhrlandklinik, Essen, Germany
- 25 min.** “Current strategies and future horizons of systemic treatment”
Hedy Lee Kindler, University of Chicago, Chicago, USA
- 25 min.** “Radiation therapy for pleural mesothelioma”
Charles B. Simone, New York Proton Center, New York, USA
- “Palliative surgery for a rare and aggressive malignancy”
David Waller, NHS, London, UK
- 15 min.** Discussion

BREAK (10:30 am – 11:00 am) – CET

SESSION 6 (11 am – 12:30 pm) – CET: **Multidisciplinary treatment of small cell lung cancer** **(SCLC) and Thymoma**

- 15 min.** “Modern surgical concepts for Thymoma”
Franca Melfi, University of Pisa, Pisa, Italy
- 45 min.** “Limited disease SCLC”
Pernelle Lavaud, Gustave Roussy, Villejuif, France
Andrea Bille, Guy’s Hospital, London, UK
Gerry Hanna, Trinity College Dublin, Dublin, Ireland
- 15 min.** “Extensive disease SCLC”
Anne-Marie Dingemans, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands
- 15 min.** Discussion

FAREWELL (12:30 pm – 1:00 pm) – CET

VITOS – Vienna International Thoracic Oncology Summit 2026

Participation
is free
of charge.
Registration
required.

Registration page:

<https://medahead-fortbildung.at/event/VITOS2026>



Registration deadlines:

November 18th, 2026, for in-person attendance

November 19th, 2026, for online attendance

**The link to the live stream will
be sent to you in time.**

Organizer/Education Provider:



Karl Landsteiner Institute
for Thoracic Surgical Research

Registration/Congress Office:

MEDahead Gesellschaft für medizinische Information m.b.H.

Part of Futuro Publishing Group

Contact person: Tanja Mozgan

Tel.: 01/607 02 33-64, E-Mail: t.mozgan@medahead.at

MEDahead

SPONSORS
(at time of printing):



Endorsed by (at time of printing):



ÖSTERREICHISCHE KREBSHILFE
SEIT 1910

Certificate of Attendance/CME Accreditation:

An application will be made to the EACCME® for CME accreditation of this event. All participants will receive a certificate of attendance via E-Mail. This event is exclusively for medical professionals.